9 research outputs found
RNA-Targeting Splicing Modifiers: Drug Development and Screening Assays
RNA splicing is an essential step in producing mature messenger RNA (mRNA) and other RNA species. Harnessing RNA splicing modifiers as a new pharmacological modality is promising for the treatment of diseases caused by aberrant splicing. This drug modality can be used for infectious diseases by disrupting the splicing of essential pathogenic genes. Several antisense oligonucleotide splicing modifiers were approved by the U.S. Food and Drug Administration (FDA) for the treatment of spinal muscular atrophy (SMA) and Duchenne muscular dystrophy (DMD). Recently, a small-molecule splicing modifier, risdiplam, was also approved for the treatment of SMA, highlighting small molecules as important warheads in the arsenal for regulating RNA splicing. The cellular targets of these approved drugs are all mRNA precursors (pre-mRNAs) in human cells. The development of novel RNA-targeting splicing modifiers can not only expand the scope of drug targets to include many previously considered “undruggable” genes but also enrich the chemical-genetic toolbox for basic biomedical research. In this review, we summarized known splicing modifiers, screening methods for novel splicing modifiers, and the chemical space occupied by the small-molecule splicing modifiers
Synthetic lethality by targeting the RUVBL1/2-TTT complex in mTORC1-hyperactive cancer cells
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.Despite considerable efforts, mTOR inhibitors have produced limited success in the clinic. To define the vulnerabilities of mTORC1-addicted cancer cells and to find previously unknown therapeutic targets, we investigated the mechanism of piperlongumine, a small molecule identified in a chemical library screen to specifically target cancer cells with a hyperactive mTORC1 phenotype. Sensitivity to piperlongumine was dependent on its ability to suppress RUVBL1/2-TTT, a complex involved in chromatin remodeling and DNA repair. Cancer cells with high mTORC1 activity are subjected to higher levels of DNA damage stress via c-Myc and displayed an increased dependency on RUVBL1/2 for survival and counteracting genotoxic stress. Examination of clinical cancer tissues also demonstrated that high mTORC1 activity was accompanied by high RUVBL2 expression. Our findings reveal a previously unknown role for RUVBL1/2 in cell survival, where it acts as a functional chaperone to mitigate stress levels induced in the mTORC1-Myc-DNA damage axis.NIH 1RO1CA142805National Research Foundation of Korea (NRF) grant (NRF-2017R1C1B1006072
Control of Chemo‑, Regio‑, and Enantioselectivity in Copper Hydride Reductions of Morita–Baylis–Hillman Adducts
Nonracemically
ligated copper hydride can be used to effect tandem
S<sub>N</sub>2′/1,2-reductions of racemic Morita–Baylis–Hillman
(MBH) acetates to access enantioenriched chiral allylic alcohols with
defined olefin geometry. MBH esters, including those with β-substitution,
can be transformed to stereodefined enoates by taking advantage of
a bulky, oligomeric, in situ generated trialkoxysiloxane leaving group.
Finally, an atypical conversion of easily arrived at MBH alcohol derivatives
to nonracemic allylic alcohols is disclosed
Discovery of Small-Molecule Enhancers of Reactive Oxygen Species That are Nontoxic or Cause Genotype-Selective Cell Death
Elevation
of reactive oxygen species (ROS) levels has been observed
in many cancer cells relative to nontransformed cells, and recent
reports have suggested that small-molecule enhancers of ROS may selectively
kill cancer cells in various <i>in vitro</i> and <i>in vivo</i> models. We used a high-throughput screening approach
to identify several hundred small-molecule enhancers of ROS in a human
osteosarcoma cell line. A minority of these compounds diminished the
viability of cancer cell lines, indicating that ROS elevation by small
molecules is insufficient to induce death of cancer cell lines. Three
chemical probes (BRD5459, BRD56491, BRD9092) are highlighted that
most strongly elevate markers of oxidative stress without causing
cell death and may be of use in a variety of cellular settings. For
example, combining nontoxic ROS-enhancing probes with nontoxic doses
of l-buthionine sulfoximine, an inhibitor of glutathione
synthesis previously studied in cancer patients, led to potent cell
death in more than 20 cases, suggesting that even nontoxic ROS-enhancing
treatments may warrant exploration in combination strategies. Additionally,
a few ROS-enhancing compounds that contain sites of electrophilicity,
including piperlongumine, show selective toxicity for transformed
cells over nontransformed cells in an engineered cell-line model of
tumorigenesis. These studies suggest that cancer cell lines are more
resilient to chemically induced increases in ROS levels than previously
thought and highlight electrophilicity as a property that may be more
closely associated with cancer-selective cell death than ROS elevation
Ausbruchswerkzeug KM-O.358
Ausbruchswerkzeug, selbstgefertigt, Stahlblech mit Holzgrif
Recommended from our members
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
Plasticity of the cell state has been proposed to drive resistance to multiple classes of cancer therapies, thereby limiting their effectiveness. A high-mesenchymal cell state observed in human tumours and cancer cell lines has been associated with resistance to multiple treatment modalities across diverse cancer lineages, but the mechanistic underpinning for this state has remained incompletely understood. Here we molecularly characterize this therapy-resistant high-mesenchymal cell state in human cancer cell lines and organoids and show that it depends on a druggable lipid-peroxidase pathway that protects against ferroptosis, a non-apoptotic form of cell death induced by the build-up of toxic lipid peroxides. We show that this cell state is characterized by activity of enzymes that promote the synthesis of polyunsaturated lipids. These lipids are the substrates for lipid peroxidation by lipoxygenase enzymes. This lipid metabolism creates a dependency on pathways converging on the phospholipid glutathione peroxidase (GPX4), a selenocysteine-containing enzyme that dissipates lipid peroxides and thereby prevents the iron-mediated reactions of peroxides that induce ferroptotic cell death. Dependency on GPX4 was found to exist across diverse therapy-resistant states characterized by high expression of ZEB1, including epithelial-mesenchymal transition in epithelial-derived carcinomas, TGFβ-mediated therapy-resistance in melanoma, treatment-induced neuroendocrine transdifferentiation in prostate cancer, and sarcomas, which are fixed in a mesenchymal state owing to their cells of origin. We identify vulnerability to ferroptic cell death induced by inhibition of a lipid peroxidase pathway as a feature of therapy-resistant cancer cells across diverse mesenchymal cell-state contexts